PhaseII study of trancatheter arterial chemoembolizaion with miriplatin for hepatocellular carcinoma -Compared with retrospective historical cohort study with epirubicin hydrochloride

Phase 2

• Conditions: Hepatocellular carcinoma

• Registration Number: JPRN-UMIN000005229
• Lead Sponsor: ara Medical University, Department of Radiology

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2011-03-11
• Study Completion: 2014-03-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 33

Inclusion Criteria

Not provided

Exclusion Criteria

1) Patients who have medical history of hypersensitivity of platinum-containing drug. 2) Patients who have medical history of hypersensitivity of iodine containing agent and/or contrast material. 3) Extrahepatic metastasis. 4) Bile duct invasion or vascular invasion. 5) Patients after HCC is ruptured. 6) Patients who have medical history of surgical reconstruction of the biliary tract or endoscopic biliary treatment. 7) Patients who have moderate or severe pleural effusion or ascites to be unresponsive to therapy. 8) Severe arterioportal shunt or arteriovenous shunt in the liver. 9) Patients with following severe complicating disease. - Patients who are difficult to control heart failure, angina or arrhythmia despite treatment - Cardiac infarction within 6 months of onset - Renal failure - Active infections(except viral hepatitis) - Active gastrointestinal bleeding - Active duplicative cancer - Hepatic encephalopathy or severe mental illness 10) Patients who are pregnant, lactating or are suspected to be pregnant. 11) Patients who are concluded to be inappropriate to participate in this study safety by their physicians.

Study & Design

• Study Type: Interventional
• Study Design: Not specified